Fibrosarcoma

News alerts, weekly reports and conference planners

Related cancers:

No biomarker	Fibrosarcoma	No biomarker	Fibrosarcoma	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
No biomarker	Fibrosarcoma	No biomarker	Fibrosarcoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
NTRK1 fusion	Neurofibrosarcoma	NTRK1 fusion	Neurofibrosarcoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
NTRK3 fusion	Neurofibrosarcoma	NTRK3 fusion	Neurofibrosarcoma	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1	entrectinib Sensitive: C1 - Off-label entrectinib Sensitive : C1
BRAF V600E	Neurofibrosarcoma	BRAF V600E	Neurofibrosarcoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
NTRK3 fusion	Fibrosarcoma	NTRK3 fusion	Fibrosarcoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK2 fusion	Fibrosarcoma	NTRK2 fusion	Fibrosarcoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NTRK1 fusion	Fibrosarcoma	NTRK1 fusion	Fibrosarcoma	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1	larotrectinib Sensitive: C1 - Off-label larotrectinib Sensitive : C1
NF2 E108X	Neurofibrosarcoma	NF2 E108X	Neurofibrosarcoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
NF2 E108X	Neurofibrosarcoma	NF2 E108X	Neurofibrosarcoma	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
TSC2 A736V	Neurofibrosarcoma	TSC2 A736V	Neurofibrosarcoma	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3	everolimus Resistant: C3 – Early Trials everolimus Resistant : C3
TSC2 A736V	Neurofibrosarcoma	TSC2 A736V	Neurofibrosarcoma	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
SQSTM1-NTRK1 fusion	Fibrosarcoma	SQSTM1-NTRK1 fusion	Fibrosarcoma	Resistant: C4 – Case Studies Resistant : C4	Resistant: C4 – Case Studies Resistant : C4
ETV6-NTRK3 fusion	Fibrosarcoma	ETV6-NTRK3 fusion	Fibrosarcoma	Resistant: C4 – Case Studies Resistant : C4	Resistant: C4 – Case Studies Resistant : C4
RBPMS-MET fusion	Fibrosarcoma	RBPMS-MET fusion	Fibrosarcoma	cabozantinib tablet Sensitive: C4 – Case Studies cabozantinib tablet Sensitive : C4	cabozantinib tablet Sensitive: C4 – Case Studies cabozantinib tablet Sensitive : C4
SQSTM1-NTRK1 fusion	Fibrosarcoma	SQSTM1-NTRK1 fusion	Fibrosarcoma	doxorubicin hydrochloride + ifosfamide Resistant: C4 – Case Studies doxorubicin hydrochloride + ifosfamide Resistant : C4	doxorubicin hydrochloride + ifosfamide Resistant: C4 – Case Studies doxorubicin hydrochloride + ifosfamide Resistant : C4
ETV6-NTRK3 fusion	Fibrosarcoma	ETV6-NTRK3 fusion	Fibrosarcoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
ETV6-NTRK3 fusion	Fibrosarcoma	ETV6-NTRK3 fusion	Fibrosarcoma	vincristine + dactinomycin Resistant: C4 – Case Studies vincristine + dactinomycin Resistant : C4	vincristine + dactinomycin Resistant: C4 – Case Studies vincristine + dactinomycin Resistant : C4
TMB-H + PD-L1 overexpression	Fibrosarcoma	TMB-H + PD-L1 overexpression	Fibrosarcoma	cisplatin + ifosfamide + epirubicin Resistant: C4 – Case Studies cisplatin + ifosfamide + epirubicin Resistant : C4	cisplatin + ifosfamide + epirubicin Resistant: C4 – Case Studies cisplatin + ifosfamide + epirubicin Resistant : C4
TMB-H + PD-L1 overexpression	Fibrosarcoma	TMB-H + PD-L1 overexpression	Fibrosarcoma	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4	camrelizumab Sensitive: C4 – Case Studies camrelizumab Sensitive : C4
TMB-H + PD-L1 overexpression	Fibrosarcoma	TMB-H + PD-L1 overexpression	Fibrosarcoma	anlotinib Resistant: C4 – Case Studies anlotinib Resistant : C4	anlotinib Resistant: C4 – Case Studies anlotinib Resistant : C4
TFG-ROS1 rearrangement	Fibrosarcoma	TFG-ROS1 rearrangement	Fibrosarcoma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
TJP1-ROS1 fusion + NF1 mutation	Neurofibrosarcoma	TJP1-ROS1 fusion + NF1 mutation	Neurofibrosarcoma	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4
ALK1 rearrangement	Fibrosarcoma	ALK1 rearrangement	Fibrosarcoma	ceritinib Resistant: C4 – Case Studies ceritinib Resistant : C4	ceritinib Resistant: C4 – Case Studies ceritinib Resistant : C4
ALK1 rearrangement	Fibrosarcoma	ALK1 rearrangement	Fibrosarcoma	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4
NF1 mutation + CDKN2A deletion + CDKN2B deletion + MTAP deletion	Neurofibrosarcoma	NF1 mutation + CDKN2A deletion + CDKN2B deletion + MTAP deletion	Neurofibrosarcoma	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4	BMS‐986504 Sensitive: C4 – Case Studies BMS‐986504 Sensitive : C4
CD8 positive	Fibrosarcoma	CD8 positive	Fibrosarcoma	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D
CSPG4 overexpression	Fibrosarcoma	CSPG4 overexpression	Fibrosarcoma	CSPG4.TNK Sensitive: D – Preclinical CSPG4.TNK Sensitive : D	CSPG4.TNK Sensitive: D – Preclinical CSPG4.TNK Sensitive : D
RANBP2-ALK rearrangement + TNFRSF8 expression	Fibrosarcoma	RANBP2-ALK rearrangement + TNFRSF8 expression	Fibrosarcoma	ceritinib + brentuximab vedotin Sensitive: D – Preclinical ceritinib + brentuximab vedotin Sensitive : D	ceritinib + brentuximab vedotin Sensitive: D – Preclinical ceritinib + brentuximab vedotin Sensitive : D
RANBP2-ALK rearrangement + TNFRSF8 expression	Fibrosarcoma	RANBP2-ALK rearrangement + TNFRSF8 expression	Fibrosarcoma	crizotinib + brentuximab vedotin Sensitive: D – Preclinical crizotinib + brentuximab vedotin Sensitive : D	crizotinib + brentuximab vedotin Sensitive: D – Preclinical crizotinib + brentuximab vedotin Sensitive : D
NF1 mutation	Neurofibrosarcoma	NF1 mutation	Neurofibrosarcoma	DR6MP + JHU395 Sensitive: D – Preclinical DR6MP + JHU395 Sensitive : D	DR6MP + JHU395 Sensitive: D – Preclinical DR6MP + JHU395 Sensitive : D
NF1 mutation	Neurofibrosarcoma	NF1 mutation	Neurofibrosarcoma	DR6MP Sensitive: D – Preclinical DR6MP Sensitive : D	DR6MP Sensitive: D – Preclinical DR6MP Sensitive : D

Fibrosarcoma

Associations(34)

Associations
(34)